Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy / 医学前沿
Frontiers of Medicine
;
(4): 32-44, 2019.
Article
Dans Anglais
| WPRIM
| ID: wpr-771262
ABSTRACT
Immunotherapy has become the fourth cancer therapy after surgery, chemotherapy, and radiotherapy. In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall survival rates of patients with refractory cancers, such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. However, inhibitor therapies are only effective in a small proportion of patients with problems, such as side effects and high costs. Therefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies to choose the optimal therapies. Here, we review the biomarkers that can serve as potential predictors of the outcomes of immune checkpoint inhibitor treatment, including tumor-specific profiles and tumor microenvironment evaluation and other factors.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Autoanticorps
/
Thérapeutique
/
Sang
/
Marqueurs biologiques tumoraux
/
Allergie et immunologie
/
Microenvironnement tumoral
/
Immunothérapie
/
Tumeurs
Type d'étude:
Étude pronostique
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Frontiers of Medicine
Année:
2019
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS